The purpose of this study is to is to examine the effects of 12 weeks of high intensity interval training on the cognitive health of perimenopausal woman.
The purpose of this study is to evaluate the impact of an aerobic exercise intervention on Chemotherapy-Related Cognitive Changes (CRCC) in women diagnosed with breast cancer who undergo chemotherapy.
The Women's HARP study is a multi-center, diagnostic observational study employing standardized imaging protocols in women with MINOCA (MI with Non Obstructive Coronary Arteries) to determine the underlying diagnosis in each participant. Participants will be followed for recurrent clinical events, every 6 months, for a maximum of 3 years.
Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer (LS2)
This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk. These women will be referred to genetic counselling for testing and those found to have Lynch Syndrome will be asked to invite first degree relatives to participate and undergo genetic testing for Lynch Syndrome.
Closed for Recruitment
Return to Everyday Activities in the Community and Home (REACH) - 8 Week Active Living and Walking Program
The purpose of this study isto increase physical activity, reduce sitting time, and increase strength and balance in middle-aged and older adults. The REACH program will help particpants change habits and embed light acitivites througout regular daily routines.
This study takes place twice a week over 8 weeks. Particpants will be asked to complete questionaires, physical performance measures and two to three interviews.
The goal of this study is to assess the frequency of vitamin B6 deficiency in older adult women in Metro Vancouver.
To compare changes in DNA activiation before and after exercise between healthy controls and patients with ME/CFS.
The purpose of this study is to investigate exposures to heavy metal exposures and other environmental chemicals among newcomer women of reproductive age (19-45 years) from India, China, Hong Kong, and Taiwan living in the Greater Vancouver area. This study will help us determine if current levels of toxicants may be a public health concern. The results of this study will help us to learn how to reduce future exposures.
This project will assess the feasibility of a 12-week physical activity program developed specifically for females exposed to a known occupational carcinogen - shiftwork. Physical activity has been shown to decrease cancer risk, but the investigators research has found that female shift workers face unique barriers to participating in physical activity.
QUEST (Quadrivalent HPV Vaccine Evaluation Study) is a Canada-wide study designed to evaluate whether 2 doses of the HPV vaccine are just as effective as 3 doses at preventing Human Papillomavirus (HPV) infection and cervical cancer.
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combination with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination with Perjeta and a taxane as adjuvant therapy in patients with HER2-positive primary invasive breast cancer.
Women with Hypoactive sexual desire disorder (HSDD) have all measures of testosterone activity comparable to controls but lower levels of dehydroepiandrosterone (DHEA). Although DHEA is a precursor of testosterone it has other actions including involvement in the stress system. It is also linked to mood. This study focuses on measures of childhood stress, current mood and salivary and nail stress hormones, in women with and without HSDD.
The purpose of this study is to test whether an oral micronized progesterone reduces the score, number and severity of hot flushes and night sweats in perimenopausal women. Oral micronized progesterone is molecularly identical to human progesterone, a steroid hormone. It is sold by prescription for use to prevent endometrial cancer in women taking estrogen in menopause. This research study will test whether progesterone reduces perimenopausal hot flushes and night sweats. It will also test whether progesterone improves sleep disturbances and anxiety.